Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort

Table 2 Evolution of DMARD treatment and disease during the first year for ESPOIR patients with early rheumatoid arthritis (RA).

First DMARD			Treatment at 1 year
Type	N	Delay between RA onset and DMARD start (weeks)^a		N	DAS28(ESR)-4v at baseline	DAS28(ESR)-4v at 1 year
Methotrexate^b	335	26.7 ± 11.6 (24.3)	Methotrexate	302	5.3 ± 1.3 (5.2)	3.2 ± 2.7 (3.0)
		35 ± 15.3 (39.4)	Other synthetic DMARD(s)^c	19	5.3 ± 1.4 (5.3)	4.1 ± 1.5 (4.1)
		30.5 ± 0.7 (21.6)	Biologic agent^d	11	5.7 ± 0.4 (5.5)	3.9 ± 0.9 (4.2)
Leflunomide	35	48.9 ± 11.6 (46.9)	Methotrexate	9	5.8 ± 1.3 (5.6)	4.0 ± 2.7 (2.9)
		22.5 ± 15.3 (20.7)	Other synthetic DMARD(s)	24	5.4 ± 1.4 (5.5)	3.3 ± 1.5 (3.0)
		37.8 ± 0.7 (37.8)	Biologic agent^d	2	5.9 ± 0.4 (5.9)	4.2 ± 0.9 (4.2)

Data are mean ± SD (median). ^aDelay between RA onset and DMARD start (weeks) (P = 0.479): Methotrexate: 27.2 ± 15.1 (24.7); Leflunomide: 30.1 ± 18.1 (24.6); ^bat one year: one patient did not receive any DMARDs and data for two patients were not available; ^cleflunomide or salazopyrine; ^dadalinumab, etanercept, infliximab or anakinra. DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; N, number.

ISSN: 1478-6362